Adrenergic beta-antagonists (beta-blockers) in COPD patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10283827" target="_blank" >RIV/00179906:_____/14:10283827 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/14:10283827

Výsledek na webu

<a href="http://www.minervamedica.it/en/journals/minerva-pneumologica/article.php?cod=R16Y2014N04A0167" target="_blank" >http://www.minervamedica.it/en/journals/minerva-pneumologica/article.php?cod=R16Y2014N04A0167</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Adrenergic beta-antagonists (beta-blockers) in COPD patients

Popis výsledku v původním jazyce

Chronic obstructive pulmonary disease (COPD) is a serious condition, which leads to decreased quality of life, increased morbidity and is a frequent cause of mortality. Frequently, patients diagnosed with COPD suffer from other comorbidities, the most prevalent being cardiovascular and neurological. Adrenergic beta-antagonists or beta-blockers (BBs) represent a group of drugs that are being used mainly in patients with various cardio-vascular diseases. As cardiovascular commorbidities are common in patients treated for COPD, the main effect of BBs in respiratory system related to vasoconstriction constitutes a concern for the safety of their use in COPD patients. This article reviews current published data on effects of BBs in COPD patients with concomitant heart condition and observed benefits and potential adverse effects of BBs in these patients.

Název v anglickém jazyce

Adrenergic beta-antagonists (beta-blockers) in COPD patients

Popis výsledku anglicky

Chronic obstructive pulmonary disease (COPD) is a serious condition, which leads to decreased quality of life, increased morbidity and is a frequent cause of mortality. Frequently, patients diagnosed with COPD suffer from other comorbidities, the most prevalent being cardiovascular and neurological. Adrenergic beta-antagonists or beta-blockers (BBs) represent a group of drugs that are being used mainly in patients with various cardio-vascular diseases. As cardiovascular commorbidities are common in patients treated for COPD, the main effect of BBs in respiratory system related to vasoconstriction constitutes a concern for the safety of their use in COPD patients. This article reviews current published data on effects of BBs in COPD patients with concomitant heart condition and observed benefits and potential adverse effects of BBs in these patients.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FC - Pneumologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Minerva Pneumologica

ISSN

0026-4954

e-ISSN

—

Svazek periodika

53

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

8

Strana od-do

167-174

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—